These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 5643974)
1. Observations on the kaolin clotting time of plasma and whole blood. MacMillan A; Ogston D Lab Pract; 1968 Jan; 17(1):42-3. PubMed ID: 5643974 [No Abstract] [Full Text] [Related]
2. [Studies of platelet factor-3 by the kaolin clotting time and thromboplastin generation time]. Oki H; Takashima A Rinsho Byori; 1973 Jul; 21(7):621-6. PubMed ID: 4738067 [No Abstract] [Full Text] [Related]
3. Evidence that von Willebrand factor is not required for the clotting of plasma in the presence of platelets and kaolin (Hardisty-Hutton test). McPherson J; Soberano ME; Macdonald C; Zucker MB Thromb Haemost; 1984 Apr; 51(2):272-4. PubMed ID: 6429885 [TBL] [Abstract][Full Text] [Related]
5. A standardized bioassay for platelet factor 3 released by kaolin. Pérez-Requejo JL Br J Haematol; 1976 May; 33(1):39-51. PubMed ID: 1268089 [TBL] [Abstract][Full Text] [Related]
6. Platelet factor 3--methods of study. De Gaetano G; Vermylen J; Verstraete M Adv Exp Med Biol; 1972; 34():281-94. PubMed ID: 4642538 [No Abstract] [Full Text] [Related]
7. Investigations of the lupus-like inhibitor by-passing activity of platelets. Howard MA; Firkin BG Thromb Haemost; 1983 Dec; 50(4):775-9. PubMed ID: 6420922 [TBL] [Abstract][Full Text] [Related]
8. [Blood coagulation factors and atherosclerosis]. Facchini G Bull Sci Med (Bologna); 1967; 139(4):460-73. PubMed ID: 5606046 [No Abstract] [Full Text] [Related]
9. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483 [TBL] [Abstract][Full Text] [Related]
10. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor]. Satake K Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626 [No Abstract] [Full Text] [Related]
12. Detection of procoagulant phospholipid interfering in tests for lupus anticoagulant. Exner T; Low J Thromb Res; 2004; 114(5-6):547-52. PubMed ID: 15507290 [TBL] [Abstract][Full Text] [Related]
13. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices. Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858 [TBL] [Abstract][Full Text] [Related]
14. Platelet activity ratio. A new approach for quantitation of platelet factor 3. Saleem A; Kreig AF; Cieslica R Am J Clin Pathol; 1975 Jan; 63(1):68-73. PubMed ID: 1111276 [TBL] [Abstract][Full Text] [Related]
15. [Blood coagulation factors in preserved blood and plasma. 1]. Vicková M Vnitr Lek; 1969 Nov; 15(11):1094-100. PubMed ID: 5364829 [No Abstract] [Full Text] [Related]
19. Factor XIII in human plasma and platelets. McDonagh J; McDonagh RP; Delâge JM; Wagner RH J Clin Invest; 1969 May; 48(5):940-6. PubMed ID: 5780202 [TBL] [Abstract][Full Text] [Related]
20. [The role of several lipid fractions derived from human erythrocytes in the blood clotting mechanism in vitor. II]. Göbel U; Brüster H Z Kinderheilkd; 1969; 106(4):281-7. PubMed ID: 5810010 [No Abstract] [Full Text] [Related] [Next] [New Search]